Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Henry

Nurse Practitioner, Family Lawrenceville, GA Nurse Practitioner

NPI 1407470891 CMS profile 10904724

771 Old Norcross Rd Ste 200, Lawrenceville, GA 30046

Open in the dashboard

General payments

$135,106

723 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Henry of Lawrenceville, GA is reported in the CMS Open Payments database as having received $135,106 across 723 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45,487 165
2024 General $41,326 157
2023 General $27,355 159
2022 General $18,749 141
2021 General $2,189 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Henry
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Erin Henry were reported at $45,487. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Erin Henry Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,189 $124 $35–$379 $132
2022 $18,749 $141 $44–$430 $149
2023 $27,355 $154 $49–$476 $160
2024 $41,326 $165 $51–$504 $164
2025 $45,487 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Insulet Corporation $87,988 134 payments
  2. Tandem Diabetes Care, Inc. $14,466 57 payments
  3. Sanofi-Aventis U.S. LLC $12,028 70 payments
  4. Dexcom, Inc. $9,800 51 payments
  5. Novo Nordisk Inc $2,130 95 payments
  6. Corcept Therapeutics $1,188 26 payments
  7. Lilly USA, LLC $1,008 51 payments
  8. Mannkind Corporation $672 16 payments
  9. Amgen Inc. $634 23 payments
  10. Medtronic, Inc. $623 9 payments
  11. Other $4,567 191 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $107,920 133 payments
  2. Food and Beverage $15,546 549 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $7,650 7 payments
  4. Travel and Lodging $2,015 26 payments
  5. Consulting Fee $1,712 2 payments
  6. Education $263 6 payments
Products named General payments · program years 2021–2025
  1. Omnipod $87,988 134 payments
  2. t:slim X2 Insulin Pump with Control-IQ $14,259 52 payments
  3. TZIELD $11,604 43 payments
  4. DEXCOM G7 GSS (161) $9,192 31 payments
  5. DEXCOM STELO GLUCOSE BIOSENSOR $9,186 30 payments
  6. Ozempic $1,392 76 payments
  7. Korlym $1,133 25 payments
  8. RYBELSUS $1,079 68 payments
  9. AFREZZA $672 16 payments
  10. MOUNJARO $636 29 payments
  11. Other $8,897 366 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

4,146

Median for Nurse Practitioner: 389

Drug cost

$2,968,402

Median for Nurse Practitioner: $21,885

Branded share of claims

65.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 419 $737,197
Mounjaro Tirzepatide Brand 501 $697,035
Jardiance Empagliflozin Brand 163 $245,243
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 98 $155,782
Tresiba Flextouch U-200 Insulin Degludec Brand 64 $136,533
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 95 $123,488
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 73 $113,108
Trulicity Dulaglutide Brand 79 $112,756
Farxiga Dapagliflozin Propanediol Brand 86 $112,508
Rybelsus Semaglutide Brand 25 $56,099

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$3,920

Medicare's payments for the services billed

Medicare patients

48

Average age 70

Services billed

97

24 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 40%
Chronic kidney disease 35%
Ischemic heart disease 33%
Heart failure 23%
Depression 23%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
$5,356 — —
Korlym
$926 — —
MOUNJARO
$227 501 —
RYBELSUS
$173 25 —
Ozempic
$173 419 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

723 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record